Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma

Individualized therapies targeting epidermal growth factor receptor (EGFR) mutations show promises for the treatment of non small-cell lung carcinoma (NSCLC). However, disease progression almost invariably occurs 1 year after tyrosine kinase inhibitor (TKI) treatment. The most prominent mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuli, Guo, Zhitao, Li, Yang, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/
https://www.ncbi.nlm.nih.gov/pubmed/28352770
http://dx.doi.org/10.1515/med-2016-0014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329801/
https://www.ncbi.nlm.nih.gov/pubmed/28352770
http://dx.doi.org/10.1515/med-2016-0014

Ejemplares similares